Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer.

Trial Profile

Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2014

At a glance

  • Drugs Anastrozole (Primary) ; Gefitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Dec 2010 Planned end date changed from 1 Feb 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 15 Mar 2010 Results published in Clinical Cancer Research.
    • 10 Dec 2008 Results were reported at the 31st Annual San Antonio Breast Cancer Symposium in Dec 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top